Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

  • December 2012
  • -
  • La Merie Publishing
  • -
  • 142 pages

Product description

The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodiesprovides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules. The cumulated sales volume of therapeutic antibodies for which biosmilar antibodies are in the R&D pipeline was as high as US$ 54.7 bln in the year 2011 with double digit growth rates of many representative of them:
Rituxan/MabThera
Arzerra
Erbitux
Vectibix
Herceptin
Avastin
Lucentis
Enbrel
Remicade
Humira
Cimzia
Simponi
Actemra/RoActemra
ReoPro
Campath
Orencia
Tysabri
Xolair
Synagis
Prolia/Xgeva
Soliris
Stelara
Zenapax
More than 140 biosimilar antibodies are in the pipeline with the first molecules approved in non-regulated markets. Ther regulation of the development of biosimilar antibodies in the European Union has facilitated the submission of an MAA of a first biosimilar antibody from a Korean company.
The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:
CD20
Her2
VEGF
TNF
EGF-R
CD52
GPIIb/IIIa
B7.1/B7.2 (CD80/CD86)
IL-6R
Alpha4/beta1/7 integrin
IgE
RSV
RANKL
Complement C5
IL-12/IL-23
CD25 (IL-2R)
Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Table of Contents

CD20 Antibodies
1. Marketed CD20 Antibodies and Sales
Rituxan/MabThera Pipeline and Sales
Arzerra Pipeline and Sales
Zevalin Pipeline and Sales
Bexxar 
2. Biosuperior CD20 Antibodies
Bispecific CD20 Antibodies
3. Biosimilar CD20 Antibodies
Rituximab (Erbitux) Biosimilars
Ofatumumab (Arzerra) Biosimilars
EGF-R Antibodies
1. Marketed EGF-R Antibodies and Sales
Erbitux Pipeline and Sales
Vectibix Pipeline and Sales
Nimotuzumab Pipeline
2. Biosuperior EGF-R Antibodies
3. Biosimilar EGF-R Antibodies
Cetuximab (Erbitux) Biosimilars
Panitumumab (Vectibix) Biosimilars
Her2 Antibodies
1. Marketed Her2 Antibodies and Sales
Herceptin Pipeline and Sales
Next Generation Herceptin: Pertuzumab Pipeline
2. Biosuperior Her2 Antibodies
T-DM1 Pipeline
Other Her2 Antibody-Drug Conjugates
Her2 Bispecific Antibodies
Engineered Her2 Antibodies
Imaging Her2 Antibodies
3. Biosimilar Her2 Antibodies
Trastuzumab (Herceptin) Biosimilars
VEGF Antibodies: Avastin
1. Marketed VEGF Antibody and Sales
Avastin Pipeline and Sales
2. Biosuperior VEGF Antibodies
Anti-VEGF Antibody Pipeline
Anti-VEGF-R Antibody Pipeline
Bispecific Anti-VEGF Pipeline
3. Biosimilar VEGF Antibodies
Bevacizumab (Avastin) Biosimilars
VEGF Antibodies: Lucentis
1. Marketed VEGF Antibody and Sales
Lucentis Pipeline and Sales
2. Biosuperior VEGF Antibodies
Next Generation Lucentis Pipeline
3. Biosimilar VEGF Antibodies
Ranibizumab (Lucentis) Biosimilars
TNF Antibodies
1. Marketed TNF Antibodies and Sales
Enbrel Pipeline and Sales
Remicade Pipeline and Sales
Humira Pipeline and Sales
Cimzia Pipeline and Sales
Simponi Pipeline and Sales
2. Biosuperior TNF Antibodies
Biosuperior TNF Antibodies
3. Biosimilar Her2 Antibodies
Etanercept (Enrel) Biosimilars
Infliximab (Remicade) Biosimilars
Adalimumab (Humira) Biosimilars
Certolizumab pegol (Cimzia) Biosimilars
Golimumab (Simponi) Biosimilars
IL-6R Antibodies
1. Marketed IL-6R Antibody and Sales
Actemra Pipeline and Sales
2. Biosuperior IL-6R Antibodies
Biosuperior IL-6R Antibodies
3. Biosimilar VEGF Antibodies
Tocilizumab (Actemra) Biosimilars
GPIIb/IIIa Antibodies
1. Marketed GPIIb/IIIa Antibody and Sales
ReoPro Pipeline and Sales
2. Biosimilar GPIIb/IIIa Antibodies
Abciximab (ReoPro) Biosimilars
CD52 Antibodies
1. Marketed CD52 Antibody 
Campath Pipeline and Sales
2. Biosimilar CD52 Antibodies
Alemtuzumab (Campath) Biosimilars
CD80/CD86 (B7.1/B7.2) Antibodies
1. Marketed CD80/86 (B7-1/B7-2) Antibodies and Sales
Orencia Pipeline and Sales
2. Biosuperior CD80/86 (B7-1/B7-2) Antibodies
Biosuperior CD80/86 (B7-1/B7-2) Antibodies
3. Biosimilar CD80/86 (B7-1/B7-2) Antibodies
Abatacept (Orencia) Biosimilars
Alpha4/beta1/7 Integrin Antibodies
1. Marketed Alpha4/beta1/7 Integrin Antibody 
Tysabri Pipeline and Sales
2. Biosimilar Alpha4/beta1/7 Integrin Antibodies
Natalizumab (Tysabri) Biosimilars
IgE Antibodies
1. Marketed IgE Antibodies and Sales
Xolair Pipeline and Sales
2. Biosuperior IgE Antibodies
Biosuperior IgE Antibodies
3. Biosimilar IgE Antibodies
Omalizumab (Xolair) Biosimilars
RSV Antibodies
1. Marketed RSV Antibodies and Sales
Synagis Pipeline and Sales
2. Biosuperior RSV Antibodies
Biosuperior RSV Antibodies
3. Biosimilar RSV Antibodies
Palivizumab (Synagis) Biosimilars
RANKL Antibodies
1. Marketed RANKL Antibodies and Sales
Prolia/XGEVA Pipelines and Sales
2. Biosuperior RANKL Antibodies
Biosuperior RANKL Antibodies
3. Biosimilar RANKL Antibodies
Denosumab (Prolia / XGEVA) Biosimilars
Complement C5 Antibodies
1. Marketed Complement C5 Antibodies and Sales
Soliris Pipelines and Sales
2. Biosuperior Complement C5 Antibodies
Biosuperior Complement C5 Antibodies
3. Biosimilar Complement C5 Antibodies
Eculizumab (Soliris) Biosimilars
IL-12/IL-23 Antibodies
1. Marketed IL-12/IL-23  Antibody 
Stelara Pipeline and Sales
2. Biosimilar IL-12/IL-23  Antibodies
Ustekinumab (Stelara) Biosimilars
CD25 (IL-2R) Antibodies
1. Marketed CD25 (IL-2R) Antibodies 
Zenapax Pipeline 
2. Biosuperior CD25 (IL-2R) Antibodies
Biosuperior CD25 (IL-2R) Antibodies
3. Biosimilar CD25 (IL-2R) Antibodies
Daclizumab (Zenapax) Biosimilars

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Markets for Bioengineered Protein Drugs

Global Markets for Bioengineered Protein Drugs

  • $ 6 650
  • Industry report
  • August 2014
  • by BCC Research

This BCC Research report explores the present and future strategies within the bioengineered protein drugs market. It analyzes each market and its applications, regulatory environment, technologies involved, ...

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

An in-depth analysis of the global nucleic acid aptamer market by technologies, applications and geographic regional markets. This report includes key technologies involved, analyzes the capabilities and ...

Biologic Therapeutic Drugs: Technologies and Global Markets

Biologic Therapeutic Drugs: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global biologics market totaled $200.6 billion in 2013 and is expected to grow to nearly $234 billion in 2014. The total market is expected to grow to $386.7 billion by the end of ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.